News | January 05, 2010

Bioresorbable Stent Shows Total Endothelialization at One Month

ART's polylactic acid bioabsorbable stent showed complete endothelialization within 30 days.

January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.

These data on the Arterial Remodeling Technologies (ART) polylactic acid (PLA) stent were published in the current special supplement of EuroIntervention. The paper is authored by Antoine Lafont, M.D., Ph.D., head, interventional cardiology department, Georges Pompidou Hospital in Paris.

“The ART bioresorbable stent showed a remarkable ability to be deployed without recoil or breakage. At one month, endothelialization was 100 percent completed. Additionally important, inflammation, smooth muscle cell proliferation and collagen accumulation were equivalent to what typically occurs after balloon angioplasty,” said Dr. Lafont. “At six months, the ART stent was completely integrated into the artery wall, thus preventing any strut migration secondary to the bioresorption process. Further, peak PLA resorption did not result in an increase or even persistence of inflammation as it has been previously reported with other bioresorbable polymer stents. Finally, inflammation and smooth muscle cell proliferation were almost not detectable at six months, resulting in no hyperplasia — in other words, no in-stent restenosis.”

The data published in EuroIntervention show that ART’s bioresorbable stent provides the requisite initial mechanical scaffolding to resist recoil. Then, as it dissolves over time in, remodeling returns to the artery. The stent caused little inflammation in the artery, which the company said might eliminate the need for anti-proliferative drugs on the stent.

EuroIntervention Journal is an international, English language, peer-reviewed journal covering percutaneous and surgical cardiovascular interventions.

For more information: www.art-stent.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init